Primary Myelofibrosis (PMF)

Hematology
4
Pipeline Programs
2
Companies
5
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

On Market (1)

Approved therapies currently available

GSK
OJJAARAApproved
momelotinib
GSK
oral2023

Competitive Landscape

2 companies ranked by most advanced pipeline stage

GSK
GSKLONDON, United Kingdom
2 programs
1
1
1
MomelotinibPhase 3Small Molecule1 trial
MMBPhase 21 trial
Active Trials
NCT02515630Completed41Est. Aug 2017
NCT02101268Completed156Est. Apr 2019
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
AZD1480Phase 13 trials
Active Trials
NCT01219543Terminated47Est. Dec 2012
NCT01112397Terminated72Est. Sep 2012
NCT00910728Completed65Est. Aug 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKMomelotinib
GSKMMB
AstraZenecaAZD1480
AstraZenecaAZD1480
AstraZenecaAZD1480

Clinical Trials (5)

Total enrollment: 381 patients across 5 trials

NCT02101268GSKMomelotinib

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

Start: Jun 2014Est. completion: Apr 2019156 patients
Phase 3Completed
NCT02515630GSKMMB

Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Start: Jan 2016Est. completion: Aug 201741 patients
Phase 2Completed
NCT01219543AstraZenecaAZD1480

A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

Start: Nov 2010Est. completion: Dec 201247 patients
Phase 1Terminated
NCT01112397AstraZenecaAZD1480

Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours

Start: Apr 2010Est. completion: Sep 201272 patients
Phase 1Terminated
NCT00910728AstraZenecaAZD1480

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Start: May 2009Est. completion: Aug 201465 patients
Phase 1Completed

Related Jobs in Hematology

Délégué Médical LLC/Myélome (H/F) - secteurToulouse

Johnson & Johnson
Issy-les-Moulineaux, France
Yesterday

MSL Hematología L - Sur

Johnson & Johnson
Sevilla, Spain
Yesterday

Senior Manager – Strategy & Business Transformation

Johnson & Johnson
Mumbai, India
Yesterday

Sr. Director Marketing

Genetix Biotherapeutics
Somerville, Massachusetts, United States
4d ago
From $270K/yr

Key Account Specialist Hematology

Johnson & Johnson
Beirut, Lebanon
4d ago

Hematology Field Medical Director, non-MD

Pfizer
Remote
4d ago
$177K - $294K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space

Related Indications

Anemia(92)Myelofibrosis(21)Polycythemia Vera(16)Primary Immune Thrombocytopenia(15)Primary Myelofibrosis(14)Immune Thrombocytopenia(12)Thrombocytopenia(11)Beta-Thalassemia(10)Aplastic Anemia(7)Anemia of Chronic Kidney Disease(7)